Novartis AG (LTS:0QLR) YoY EBITDA Growth: 1.55% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0QLR Novartis AG LTS:0QLR
80 GF Score
Price CHF125.27
GF Value CHF106.58
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Novartis AG YoY EBITDA Growth?

Novartis AG LTS:0QLR -3.12% 80 YoY EBITDA Growth is 1.55% as of Jun. 2026. GuruFocus rates LTS:0QLR with a GF Score™ of 80/100 and a GF Value™ of CHF106.58 (Modestly Overvalued). The stock has 5 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Novartis AG's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 1.55%.

Novartis AG's EBITDA per Share for the three months ended in Jun. 2026 was CHF2.56.

Novartis AG YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Novartis AG's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG YoY EBITDA Growth Chart

Novartis AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 89.16 -50.58 21.20 20.28 2.49

Novartis AG Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.94 2.17 -9.42 -14.60 1.55
LTS:0QLR
80GF Score
Novartis AG LTS:0QLR
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novartis AG YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Novartis AG's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(9.302-9.076)/ | 9.076 |
=2.49 %

Novartis AG's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(2.56-2.521)/ | 2.521 |
=1.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 1.55% mean?
Novartis AG (LTS:0QLR) has a YoY EBITDA Growth of 1.55% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Novartis AG and its competitors.
Is Novartis AG's YoY EBITDA Growth too high?
Novartis AG's current YoY EBITDA Growth is 1.55%. Overall, Novartis AG has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's YoY EBITDA Growth compare to LLY and JNJ?
Novartis AG's YoY EBITDA Growth of 1.55% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Novartis AG and its competitors. Novartis AG's current YoY EBITDA Growth is 1.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Based on GuruFocus' analysis, Novartis AG (LTS:0QLR) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF106.58, compared to a current price of CHF125.27 — trading 17.5% above its estimated fair value. The current YoY EBITDA Growth is 1.55%. Novartis AG's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Novartis AG (LTS:0QLR), the current YoY EBITDA Growth is 1.55% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novartis AG (LTS:0QLR) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued. The current stock price of CHF125.27 is trading 17.5% above its estimated GF Value™ of CHF106.58. GuruFocus considers Novartis AG to be Modestly Overvalued.

Key valuation signals for LTS:0QLR:

  • YoY EBITDA Growth: 1.55%
  • GF Value™: CHF106.58 vs. price of CHF125.27 (17.5% above fair value)
  • GF Score™: 80/100 with 5 warning signs

No single metric tells the full story. See the LTS:0QLR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novartis AG Business Description

Address Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
80GF Score

Get the complete analysis for LTS:0QLR

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF125.27
Price
CHF106.58
GF Value